Related Experiment Video
Updated: Apr 24, 2026

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
1Institute of Urology, Keck Medical Center of USC, University of Southern California, Los Angeles, CA, USA.
Abstract:
Prostate specific antigen has been extensively studied and represents the most common biomarker across the spectrum of prostate cancer. Circulating tumor cells are a more recent method for monitoring patients with metastatic prostate cancer and have shown great promise in predicting outcomes. We review the prognostic capabilities of these markers to determine if circulating tumor cells should unseat prostate specific antigen as the test of choice in prostate cancer.
More Related Videos
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
11:56In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells
Published on: May 15, 2014